Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).
Authors: Tumusiime VB; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda., Ruzagira E; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda.; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, London, England, UK., Norcross C; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda.; Global Health and Infectious, Brighton and Sussex Medical School, Brighton, England, UK., Eshun-Wilsonova I; Johnson & Johnson, CapeTown, South Africa., Kitonsa J; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda.; Global Health and Infectious, Brighton and Sussex Medical School, Brighton, England, UK., Bahemuka UM; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda., Grint D; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, London, England, UK., Kimbugwe G; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda., Kakande A; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda., Lawrence DS; Department of Clinical Research, London School of Hygiene and Tropical Medicine Faculty of Infectious and Tropical Diseases, London, England, UK.; Botswana Harvard Health Partnership, Gaborone, Botswana.; School of Pathology, Faculty of Health Sciences , University of Witwatersrand, Johannesburg, South Africa., Mwendia F; Johnson & Johnson, East Africa, Nairobi, Kenya., Van Solingen R; Jansenn Research and Development, Beerse, Belgium., Van Eygen V; Jansenn Research and Development, Beerse, Belgium., Addo Boateng F; Johnson & Johnson Middle East FZ LLC, Accra, Ghana., Cresswell F; HIV interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, 256, Uganda.; Global Health and Infectious, Brighton and Sussex Medical School, Brighton, England, UK.; Department of Clinical Research, London School of Hygiene and Tropical Medicine Faculty of Infectious and Tropical Diseases, London, England, UK.
Corporate Authors: IMPALA study team
Source: Wellcome open research [Wellcome Open Res] 2025 Mar 28; Vol. 10, pp. 166. Date of Electronic Publication: 2025 Mar 28 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Wellcome Trust Country of Publication: England NLM ID: 101696457 Publication Model: eCollection Cited Medium: Print ISSN: 2398-502X (Print) Linking ISSN: 2398502X NLM ISO Abbreviation: Wellcome Open Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2398-502X
DOI:10.12688/wellcomeopenres.23363.1